Then, we conducted subgroup survival analyses of POLD1 expression based on hepatitis virus infection, clinicopathological staging and sorafenib use in 364 patients with HCC (Figures 2E–H). The gene discussed is POLD1; the disease is hepatocellular carcinoma.